Home > Boards > US Listed > Biotechs >

BG Medicine, Inc. (BGMD)

BGMD RSS Feed 		Add BGMD Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 12/5/2018 10:58:26 AM - Followers: 42 - Board type: Free - Posts Today: 0


Welcome to BG Medicine Inc. (BGMD) Board!!






BG Medicine, Inc. is dedicated to developing and delivering innovative solutions for healthcare providers that

provide insight and transform the clinical care of heart failure and related disorders.


galectin-3 mechanism of action videohttp://www.bg-medicine.com/wp-content/uploads/2014/11/BGM_role-of-galectin-3.mp4?id=0


 

LEADERSHIP

Paul R. Sohmer, M.D. / President and CEOPaul R. Sohmer, M.D. joined BG Medicine in May of 2013 as President, CEO and member of the board of directors. Dr. Sohmer served as President and Chief Executive Officer of Viracor-IBT Laboratories, Inc., a diagnostic and research laboratory specializing in allergy, immunology, and infectious disease testing from January 2011 to September of 2012. Prior to joining Viracor-IBT Laboratories, from February 2009 to January 2011, Dr. Sohmer served as Chief Executive Officer of Orthocon, Inc., a company that develops, manufactures, markets, and sells implantable products designed to stop bone bleeding. From 2007 to 2009, Dr. Sohmer served on the RadPharm, Inc. board of directors, and from 2008 to 2009, he served as chairman of the board of directors of Molecular Biometrics, Inc. Dr. Sohmer served as Interim CEO of Cylex, Inc. from January through March of 2008 and CEO of Pathway Diagnostics from May to September of 2008. From June 2000 to December 2006, Dr. Sohmer served as Chairman, President and Chief Executive Officer of TriPath Imaging, Inc. (NASDAQ:TPTH). From 1997 to 2000, Dr. Sohmer served as President and Chief Executive Officer of Neuromedical Systems, Inc. (NASDAQ:NSIX). From 1992 to 1996, Dr. Sohmer served as President and Chief Executive Officer of Genetrix, Inc., a genetic testing lab. From 1991-1992, Dr. Sohmer served as Vice President of Professional Services for Nichols Institute. From 1985 to 1991, Dr. Sohmer served as President and Chief Executive Officer of Pathology Institute, Inc., where he led the first commercial introduction of polymerase chain reaction (PCR) for diagnosis of HIV and founded the Chiron Reference Laboratory. Dr. Sohmer received his B.A. from Northwestern University and M.D. from the Chicago Medical School. Dr. Sohmer was named the Ernst and Young Carolinas Life Sciences Entrepreneur of the Year in 2005.

Stephen Hall / Executive Vice President, Chief Financial Office
Mr. Hall joined BG Medicine from Stemline Therapeutics, Inc., a publicly traded clinical stage biopharmaceutical company, where he held the position of Vice President Finance, Treasurer, Principal Financial and Chief Accounting Officer and assisted in financings in excess of $100m. Prior to Stemline, Mr. Hall served as Chief Financial Officer at both life science and medical device companies, including Orthocon, Inc., Helicos BioSciences Corporation, TriPath Imaging, Inc., and Colorado MEDtech, Inc. Mr. Hall, a certified public accountant, began his professional career with Peat, Marwick, Mitchell & Co., in Chicago, IL. In addition to his experience as an operating CFO, he spent nearly 10 years in commercial banking. He received his AB degree from Harvard College and MBA from Stanford University Graduate School of Business.

Aram Adourian, Ph.D. / Senior Vice President and Chief Scientific Officer
Dr. Adourian joined BG Medicine from the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. While at MIT, he served as Project Manager for Bioinformatics specializing in the development of novel systems and approaches for biomolecular sequencing, analysis and modeling. Dr. Adourian earned his Ph.D. at Harvard University in Statistical Physics, where he was a recipient of the Rudenberg Research Prize, and received his undergraduate degree in Physics from Cornell University.

Raul Diaz / Vice President, Operations and Information Technologies
Mr. Diaz joined BG Medicine from Newcogen Group Inc.  While at Newcogen Group, he served as Director of Information Technologies where he was responsible for all aspects of the organization’s information technology infrastructure.  Prior to Newcogen, Mr. Diaz spent years as a consultant specializing in information technology architecture, compliance, knowledge management and business continuity.  Mr. Diaz received a Bachelor’s degree in Electrical Engineering from the University of Massachusetts Lowell.

Headquarters

BG Medicine, Inc.                       
880 Winter Street
Suite 210
Waltham, MA 02451
+ 1 (781) 890.1199
http://www.bg-medicine.com/
communications@bg-medicine.com



 
 

 
BGMD
Current Price
Volume:
Bid Ask Day's Range
BGMD Detailed Quote
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#1948   agree about the patents! management is scum though, ToldYaSo 12/05/18 10:58:26 AM
#1947   The patents of BGMD have to be worth kcbigbucks 12/01/18 07:58:07 AM
#1946   Galectin-3 predicts response and outcomes after cardiac resynchronization therap max0001 12/01/18 04:33:14 AM
#1945   In the Emergency Department, accurate diagnosis in a max0001 10/30/18 02:56:22 AM
#1944   https://www.accessdata.fda.gov/cdrh_docs/pdf14/K140436.pdf max0001 10/29/18 09:04:06 AM
#1943   70th AACC Annual Scientific Meeting Abstracts, 2018. Race- max0001 10/29/18 08:44:02 AM
#1942   Ya it doesn't make much sense, especially with nml12 10/19/18 05:37:59 AM
#1941   Why is there any shares trading on this? kcbigbucks 10/18/18 03:39:02 PM
#1940   The Predictive Value of Plasma Brain Natriuretic max0001 10/05/18 06:06:24 AM
#1939   Great article it shows the importance of the kcbigbucks 09/26/18 06:41:41 AM
#1938   Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular max0001 09/24/18 03:39:46 AM
#1937   http://corp.sec.state.ma.us/corpweb/CorpSearch/CorpSearch.aspx and BG Medicine a nml12 09/17/18 10:33:18 AM
#1936   @nml12: Where can I find the details you bertbex 09/17/18 09:51:56 AM
#1935   Thanks for the info--I hate to hear it, too! ToldYaSo 09/13/18 01:31:55 PM
#1934   Looks like this is going bye bye. I nml12 09/13/18 01:20:30 PM
#1932   On OTC Markets this is a Pink--no information ToldYaSo 08/30/18 10:20:53 AM
#1931   https://www.otcmarkets.com/stock/BGMD/security max0001 08/29/18 01:53:39 PM
#1930   What? Could you explain more for us slow ones? kcbigbucks 08/29/18 01:37:06 PM
#1929   OTC Markets 08/27/2018 Transfer Agent Verified max0001 08/29/18 11:54:24 AM
#1928   They announced that they were going dark--quitting filing ToldYaSo 08/28/18 12:49:20 PM
#1927   Interesting articles Max - I hope this stock kcbigbucks 08/27/18 11:43:44 PM
#1926   https://patents.justia.com/patent/20150080463 max0001 08/26/18 08:35:28 AM
#1925   New old test?-PCSK9,Mirnext,miRNAs,http://www.ctmm.nl/en/downloads/projects-down max0001 08/25/18 03:37:32 PM
#1924   It is interesting: 1. Methods for predicting cardiovascular max0001 08/23/18 05:54:39 AM
#1923   I think most of the volume on this ToldYaSo 07/24/18 11:33:42 AM
#1922   Since you are a bag-holder like me and PC_ 07/23/18 05:09:51 PM
#1921   Stock has gone dark, as per prior otc ToldYaSo 07/17/18 11:37:04 AM
#1920   It is interesting: DEF-14A 06/23/2016… Board of Directors max0001 07/17/18 10:56:58 AM
#1919   Galectin-3: A new post-MI prognostic biomarker?https://www.mdedge.com/ecardiolog max0001 07/13/18 12:06:11 AM
#1918   http://www.stockscores.com/charts/charts/?ticker=BGMD mick 06/07/18 06:05:17 PM
#1917   (BGMD) 0.38 ? 0.0 (0.00%) mick 06/07/18 06:04:58 PM
#1916   Galectin-3: One Molecule for an Alphabet of Diseases, max0001 05/22/18 04:38:40 PM
#1915   Today CARV +200%,when BGMD FLY??? max0001 05/17/18 04:35:17 PM
#1914   I want to buy shares.Anybody now why STOP t.? max0001 05/17/18 04:26:32 PM
#1913   Galectin-3 test in development-Alinity assay menu (Abbott).cardioSCORE? https:// max0001 05/17/18 03:55:49 PM
#1912   FDA has recently approved the GORE® CARDIOFORM Septal foreontee 04/18/18 10:07:37 AM
#1911   http://www.stockscores.com/charts/charts/?ticker=BGMD mick 04/07/18 11:04:46 AM
#1910   I think that management has decided that this ToldYaSo 02/23/18 09:26:53 AM
#1909   http://www.barchart.com/detailedquote/stocks/BGMD mick 02/22/18 09:15:33 PM
#1908   (BGMD) 0.38 ? 0.0 (0.00%) mick 01/23/18 07:01:41 PM
#1907   new patent application 12/28/2017 anon352630 01/09/18 09:04:49 PM
#1906   Holy blank Batman. I had to rub my kcbigbucks 12/14/17 04:40:27 PM
#1905   The 2016 annual meeting of stockholders (August 5, max0001 12/09/17 01:05:02 AM
#1904   There was a shareholders meeting? kcbigbucks 12/08/17 11:30:19 PM
#1903   Any news from shareholders meeting? max0001 12/08/17 08:26:34 AM
#1902   Galectin-3 test under development in ADVIA Centaur max0001 12/08/17 08:23:08 AM
#1901   BG Medicine and Siemens Healthcare Diagnostics (Galectin-3 test)? max0001 12/07/17 05:31:57 AM
#1900   Galectin-3 test-Architect i 2000srAbbott and VIDAS® bioMerieux. max0001 12/07/17 05:17:47 AM
#1899   http://onlinelibrary.wiley.com/doi/10.1002/rth2.12038/full max0001 12/07/17 12:46:01 AM
#1898   http://www.barchart.com/snapopinion/stocks/BGMD mick 12/01/17 05:48:48 AM
PostSubject
© 2019 InvestorsHub.com, Inc.